NIH SBIR Phase II (Omnibus)
Funds United States small businesses advancing validated biomedical innovations through substantial full development execution.
The NIH SBIR Phase II Omnibus is the National Institutes of Health's primary non-dilutive R&D execution grant for U.S. small businesses that have completed or can demonstrate Phase I-equivalent feasibility work. Issued under activity code R44, Phase II awards are capped at $2,045,816 in total costs and cover one to three years of full research and development โ typically prototype construction, anโฆ
Continuation of a successful Phase I project from the same NIH institute or center. Application must demonstrate Phase I milestone completion and a credible path to commercialization.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up
Guides for this application
All guides โSBIR/STTR Grants for Deeptech Startups
A practical guide to SBIR and STTR grants for deeptech startups, including agency fit, Phase I and II logic, eligibility, budgets, and review criteria.
DocumentsNIH Biosketch Guide: Format, SciENcv Steps, and Examples
Learn what an NIH biosketch is, how the format works, what to prepare for SciENcv, and how startup teams should avoid common biosketch mistakes.
Write proposalHow to Write a Specific Aims Page
Learn how to write a specific aims page for NIH, SBIR-adjacent, and translational R&D grants, with structure, reviewer logic, examples, and common mistakes.
Where to applyGrants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
More from NIH
All grants from this funder โHEAL Initiative: Pain Research Enhancement Program (PREP)
๐บ๐ธNIH ยท United States
Funds basic and mechanistic pain research at institutions that receive little NIH funding, with students working on the project alongside the investigator.
NIH HEAL Initiative โ Open NOFOs
๐บ๐ธNIH ยท United States
Supports opioid, pain, and substance use disorder research in the NIH HEAL portfolio.
NIH Research Software Engineer (RSE) Award
๐บ๐ธNIH ยท United States
Funds the salary of a research software engineer building and sharing biomedical, behavioural or health software, tools and algorithms.
NIH SBIR Direct-to-Phase II (Omnibus)
๐บ๐ธNIH ยท United States
Funds United States small businesses moving directly into major development when early biomedical feasibility is already established.
NIH SBIR Fast-Track (Omnibus)
๐บ๐ธNIH ยท United States
Supports United States small businesses with streamlined biomedical pathways from feasibility to continued development.
NIH SBIR Phase I (Omnibus)
๐บ๐ธNIH ยท United States
Funds United States small businesses advancing biomedical and behavioral-health innovations through early technical validation.
Similar grants
Browse the directory โNIH SBIR Phase II
๐บ๐ธNIH SEED ยท United States
Supports United States biomedical small businesses advancing successful feasibility work into scale-up development.
NCATS SBIR Phase II
๐บ๐ธNCATS ยท United States
Backs small businesses scaling proven translational findings into applied solutions and early market readiness.
NEI SBIR Phase II โ R&D
๐บ๐ธNEI ยท United States
Supports United States. small businesses scaling vision concepts into full development pathways.
NCATS STTR Phase II
๐บ๐ธNCATS ยท United States
Funds U.S. small businesses and their nonprofit research partners to continue and expand translational R&D begun in STTR Phase I toward a commercial product.
NCI SBIR/STTR Omnibus (Next Receipt 5)
๐บ๐ธNCI ยท United States
Supports small businesses developing cancer technologies through national NIH collaboration pathways.
NEI STTR Phase II โ R&D
๐บ๐ธNEI ยท United States
Funds collaborative small-business partnerships to mature vision innovation into market-ready healthcare technologies.